Direct (new) oral anticoagulants (DOACs): Drawbacks, bleeding and reversal

CONCLUSION: Management recommendations for hemorrhage associated with DOAC use vary, depending on the class of the culprit agent (direct thrombin inhibitor vs. FXa inhibitor), the clinical status of the patient (mild/ moderate vs. severe/life-threatening), and capabilities of the institution. Specific reversal agents (i.e., idarucizumab and andexanet alfa) can be used if available, while prothrombin complex concentrates, fresh frozen plasma and/ or tranexamic acid can also be employed as nonspecific replacement agents in the management of DOAC-related bleeding diathesis.PMID:34521332 | DOI:10.2174/1871525719666210914110750
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - Category: Cardiology Authors: Source Type: research